These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22724020)

  • 1. Deregulation of Rab and Rab effector genes in bladder cancer.
    Ho JR; Chapeaublanc E; Kirkwood L; Nicolle R; Benhamou S; Lebret T; Allory Y; Southgate J; Radvanyi F; Goud B
    PLoS One; 2012; 7(6):e39469. PubMed ID: 22724020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
    Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
    J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
    di Martino E; Alder O; Hurst CD; Knowles MA
    Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
    Iyer G; Milowsky MI
    Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
    Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
    Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
    Barrows D; Feng L; Carroll TS; Allis CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of cell-cell and cell-matrix adhesion in urothelial cells: an oncogenic mechanism for mutant FGFR3.
    di Martino E; Kelly G; Roulson JA; Knowles MA
    Mol Cancer Res; 2015 Jan; 13(1):138-48. PubMed ID: 25223521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
    Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
    Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
    Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
    Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.
    Vallot C; Stransky N; Bernard-Pierrot I; Hérault A; Zucman-Rossi J; Chapeaublanc E; Vordos D; Laplanche A; Benhamou S; Lebret T; Southgate J; Allory Y; Radvanyi F
    J Natl Cancer Inst; 2011 Jan; 103(1):47-60. PubMed ID: 21173382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin.
    Hafner C; Hartmann A; Vogt T
    J Invest Dermatol; 2007 Jul; 127(7):1572-3. PubMed ID: 17568799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rab23 is overexpressed in human bladder cancer and promotes cancer cell proliferation and invasion.
    Jiang Y; Han Y; Sun C; Han C; Han N; Zhi W; Qiao Q
    Tumour Biol; 2016 Jun; 37(6):8131-8. PubMed ID: 26715272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer.
    di Martino E; Taylor CF; Roulson JA; Knowles MA
    Genes Chromosomes Cancer; 2013 Sep; 52(9):860-71. PubMed ID: 23775577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
    Knowles MA
    World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.